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Vaccinating school-aged children against inﬂuenza can reduce age-speciﬁc and population-level illness attack
rates. Using a stochastic simulation model of inﬂuenza transmission, the authors assessed strategies for vacci-
nating children in the United States, varying the vaccine type, coverage level, and reproductive number R (average
number of secondary cases produced by a typical primary case). Results indicated that vaccinating children can
substantially reduce population-level illness attack rates over a wide range of scenarios. The greatest absolute
reduction in inﬂuenza illness cases per season occurred at R values ranging from 1.2 to 1.6 for a given vaccine
coverage level. The indirect, total, and overall effects of vaccinating children were strong when transmission
intensity was low to intermediate. The indirect effects declined rapidly as transmission intensity increased. In a mild
inﬂuenza season (R ¼ 1.1), approximately 19 million inﬂuenza cases could be prevented by vaccinating 70% of
children. At most, nearly 100 million cases of inﬂuenza illness could be prevented, depending on the proportion of
children vaccinated and the transmission intensity. Given the current worldwide threat of novel inﬂuenza A (H1N1),
with an estimated R of 1.4–1.6, health ofﬁcials should consider strategies for vaccinating children against novel
inﬂuenza A (H1N1) as well as seasonal inﬂuenza.
communicable disease control; inﬂuenza, human; inﬂuenza vaccines; mass immunization
Abbreviations: LAIV, trivalent live, attenuated inﬂuenza vaccine; R, average number of secondary cases produced by a typical
primary case in a population with a certain level of preexisting partial immunity; TIV, trivalent inactivated inﬂuenza vaccine; VEI,
vaccine efﬁcacy for infectiousness; VEP, vaccine efﬁcacy for illness given infection; VES, vaccine efﬁcacy for susceptibility; VESP,
vaccine efﬁcacy for infection-conﬁrmed symptomatic illness.
School-aged children have high inﬂuenza illness attack
rates and play a key role in inﬂuenza transmission. In addi-
tion, vaccinating children in this age group has been shown to
reduce population-level inﬂuenza illness attack rates (1–5).
As a result, targeted vaccination of school-aged children has
the potential to substantially reduce the overall morbidity and
mortalityassociatedwithinﬂuenzaillnessandshouldbeeval-
uated further.
In 2008, the US Advisory Committee on Immunization
Practices recommended yearly seasonal inﬂuenza vaccina-
tion for all children aged 6 months to 18 years (6, 7). Cur-
rently,2types ofinﬂuenzavaccine are licensed inthe United
States. Trivalent inactivated inﬂuenza vaccine (TIV), ad-
ministered intramuscularly, is recommended for use in all
children 6 months of age or older. Trivalent live, attenuated
inﬂuenza vaccine (LAIV), administered by the intranasal
route, is recommended for use in healthy children over 2
years of age (6, 7).
The ability of a vaccination strategy to prevent illness in
a population is determined by a number of factors. The
efﬁcacy of the vaccine in directly protecting against infec-
tion and illness and in reducing infectiousness is key. The
baseline intensity of transmission, described by the repro-
ductive number R, and the level of vaccine coverage are also
important.
A recent analysis based on challenge studies, community-
based trials, and ﬁeld studies estimated the efﬁcacy of LAIV
and TIV (8). Overall, on the basis of the analysis of challenge
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level of efﬁcacy against infection. Although the differences
werenotstatisticallysigniﬁcant,therewassomeevidencethat,
compared withinactivatedvaccine, LAIVhad higherefﬁcacy
against infection and illness, illness given infection, and
infectiousness.
In the present study, we determined the effect of vacci-
nating school-aged children in the United States against in-
ﬂuenza illness by modeling several different vaccination
strategies. In this paper, we compare the reduction in overall
and age-speciﬁc inﬂuenza illness attack rates and the num-
ber ofinﬂuenza cases that couldbe preventedby implement-
ing these strategies. In addition, the indirect effects of
vaccination are quantiﬁed under these scenarios.
The recent outbreak of novel inﬂuenza A (H1N1) began
in Mexico and had spread to over 70 countries, resulting in
more than 27,700 cases and 140 deaths, by early June 2009
(9). Plans to produce a vaccine are under way, which high-
lights the urgent need for a vaccination strategy that produ-
ces the greatest reduction in inﬂuenza illness attack rates. In
this context, and with the ever-present need to reduce the
morbidity and mortality caused by seasonal inﬂuenza, we
consider strategies for vaccinating children to reduce overall
population-level inﬂuenza attack rates.
MATERIALS AND METHODS
Stochastic simulation model
We use a stochastic simulation model of inﬂuenza trans-
mission based on a model described previously (10, 11).
Brieﬂy, we modeled the spread of inﬂuenza in the popula-
tion of Los Angeles County, California, a metropolitan area
of approximately 11 million residents, using employment
rates and commuting data for Los Angeles County from
the 2000 US Census (12, 13) and population estimates from
Walter R. McDonald & Associates, Inc. (14), to which we
added an estimated 776,000 undocumented people in Los
Angeles County (15). Using this population, we calculated
the illness attack rates in Los Angeles County and extrapo-
lated the results to the 2009 US population, an estimated
305.5 million people (16).
Each individual in the simulation is assigned an age and
a set of social contact groups including family, household
cluster, neighborhood, community, workplace, neighbor-
hood playgroup, and school, as appropriate. Inﬂuenza is
transmitted from infected individuals to susceptible ones
based on the probabilities of contact between the 2 individ-
uals, determined by their membership in common social
groups, and on the state of the 2 individuals, affected by
duration of infection and their vaccination status. Individu-
als were randomly selected from the population and infected
to simulate a continuous random seeding process.
The dynamics of inﬂuenza infection, illness, and infec-
tiousness reﬂect our current understanding of the natural
history of inﬂuenza (17). Once infected, an individual be-
comes infectious according to a probability distribution
based on viral shedding. Thirty-three percent of those in-
fected do not become symptomatic, while the other 67%
become symptomatic after a 1–3-day incubation period
(18, 19). Symptomatic individuals are twice as infectious
as asymptomatic individuals. After 6 days, infected individ-
uals are no longer infectious or susceptible.
The model was run 5 times for each scenario, and the
average illness attack rates and numbers of cases are re-
ported here. There was little stochastic variability across
the runs because of the large population size, indicating that
5 runs are adequate.
Vaccine efﬁcacy model parameters
In general, vaccine efﬁcacy is deﬁned as vaccine
efﬁcacy ¼ 1   relative risk, where the relative risk com-
pares an outcome in the vaccinated group with the same
outcome among the controls. Depending upon the speciﬁc
outcome of interest, a measure of vaccine efﬁcacy can quan-
tify protection against infection, illness, illness given infec-
tion, or reduction in infectiousness among infected
individuals (20). Speciﬁcally, vaccine efﬁcacy for suscepti-
bility (VES) estimates the ability of the vaccine to prevent
infection. Vaccine efﬁcacy for infection-conﬁrmed symp-
tomatic illness (VESP) quantiﬁes the ability of the vaccine
to prevent infection-conﬁrmed symptomatic illness. Vaccine
efﬁcacy for symptomatic illness given infection (VEP) esti-
mates the degree to which the vaccine prevents an infected
individual from developing symptoms or reduces pathoge-
nicity. Vaccine efﬁcacy for infectiousness (VEI) estimates
the reduction in the probability that an infected, vaccinated
person compared with an infected, unvaccinated person will
transmit the infection to another individual. Both VEP and
VEI condition on being infected; VES and VESP do not
condition on infection. The combined vaccine efﬁcacy
VEC is a function of these components of vaccine efﬁcacy
and quantiﬁes the reduction in transmission in the entire
population due to vaccination (8).
Thevalues for VES,VE SP,VE P,a n dV E I for LAIVand TIV
used in the model are shown in Table 1 and were drawn from
our best estimates based on previous work (8). Given these
efﬁcacy values, LAIV and TIV would provide the same
moderate protection against infection for both homologous
Table 1. Expected Vaccine Efﬁcacies (%) for LAIV and TIV When
the Vaccines Are Homologous and Heterologous Based on
Challenge Study, Community-based Trial, and Field Study Data, as
Reported by Basta et al. (8)
LAIV TIV
Homologous Heterologous Homologous Heterologous
VES 40 30 40 30
VEP 83 57 67 14
VESP 90 70 80 40
VEI 50 30 40 20
VEC 83 68 78 56
Abbreviations: LAIV, trivalent live, attenuated inﬂuenza vaccine;
TIV, trivalent inactivated inﬂuenza vaccine; VEC, combined vaccine
efﬁcacy; VEI, vaccine efﬁcacy for infectiousness; VEP, vaccine efﬁ-
cacy for symptomatic illness given infection; VES, vaccine efﬁcacy for
susceptibility; VESP, vaccine efﬁcacy for infection-conﬁrmed symp-
tomatic illness.
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cine efﬁcacy for symptomatic illness given infection (VEP),
for infection-conﬁrmed symptomatic illness (VESP), and for
infectiousness (VEI), based on these parameters, would be
somewhat higher for LAIV compared with TIV, although
not signiﬁcantly so, when the vaccines are both well matched
and poorly matched.
Indirect, total, and overall vaccine effects
In this study, our aim was to determine how an interven-
tion strategy of vaccinating children would alter population-
level inﬂuenza illness rates. In this context, the intervention
is to vaccinate children. To determine the indirect, total, and
overall vaccine effects, we compare the attack rates in the
population that received the intervention with those in the
nonintervention population, which is the baseline popula-
tion. Individuals in the baseline population have some level
of preexisting immunity because of previous vaccination or
natural infection. We compare outcomes in these 2 popula-
tions for different values of the reproductive number R.W e
deﬁne R as the average number of secondary cases produced
by a typical primary case in a population with a certain level
of preexisting partial immunity. The basic reproductive
number, R0, is the reproductive number in a population with
no preexisting immunity. Because our intervention of vac-
cinating children is in addition to any preexisting immunity
in the population, conceptually we have R ¼ a R0, where
1   a is the proportional reduction in susceptibility of ex-
posed people, that is, the leaky model of immunity (20), that
accounts for the degree of preexisting immunity.
Comparing illness attack rates in the intervention popu-
lation with those in a comparable population in which no
intervention has taken place provides further insight into the
ability of thevaccination strategy to reduce inﬂuenza illness.
Again, vaccine efﬁcacy takes the form 1   relative risk, but
here we are interested in quantifying the population-level
effects of vaccination. The indirect effects of vaccination,
VEIndirect, compare the attack rates in those who did not
receive the intervention in the population in which children
were vaccinated with those in the nonintervention popula-
tion. The total effectiveness of vaccination and the vacci-
nation program, VETotal, compares the attack rates in the
v a c c i n a t e dc h i l d r e ni nt h ei n tervention population with
those in the nonintervention population. Finally, the
overall effectiveness of the vaccination program, VEOverall,
compares the average attack rate in the intervention com-
munity with the overall attack rate in the nonintervention
population (21).
Vaccination strategies and outcomes
We evaluated several strategies for vaccinating children
against inﬂuenza by varying the type of vaccine used (LAIV
or TIV), the level of vaccination coverage (30%, 50%, or
70% of all children), R (the average number of secondary
cases produced by a typical primary case, ranging from 1.1
to 2.4), and whether the vaccine strain was well matched
(homologous) or poorly matched (heterologous) to the cir-
culating inﬂuenza strain. We assessed how combinations of
these factors altered overall population-level attack rates,
the total number of inﬂuenza cases expected in the entire
US population in a single season, and the age-speciﬁc attack
rates compared with a baseline scenario with no additional
intervention. The absolute measures of the effect of vacci-
nating children, given by the difference in the number of
cases, provide important information useful for assessing
the public health impact of the intervention. In all of the
scenarios, the intervention consists of vaccinating children,
although the proportion vaccinated varies. Approximately
20% of children aged 6 months to 18 years are expected
to be ineligible to receive LAIV because of contraindica-
tions such as a history of asthma or age less than 2 years
(22). Therefore, 20% of vaccinated children in the LAIV
scenarios were randomly selected to receiveinactivated vac-
cine instead of the live, attenuated formulation. We calcu-
lated the indirect, total, and overall effects of vaccinating
children at the population level, as described by Halloran
et al. (20), stratifying by age (children aged  18 years vs.
adults aged >18 years) when appropriate.
RESULTS
Figure 1 presents the overall illness attack rates and num-
bers of cases of inﬂuenza illness expected during a single
inﬂuenza season in the US population under the baseline
scenario for each value of R in 0.1 increments from 1.1 to
2.4. On the basis of estimates derived from past inﬂuenza
seasons, a seasonal inﬂuenza outbreak with R ranging from
1.1 to 1.6 would correspond to a mild, moderate, or severe
seasonal outbreak. A pandemic inﬂuenza outbreak with R
ranging from 1.5 to 1.8 would likely be considered a mod-
erate pandemic, and a pandemic inﬂuenza outbreak with an
R of 1.8–2.4 would be severe (23–27). Our model indicates
Seasonal Influenza 
2.4 2.3 2.2 2.1 2.0 1.9 1.8 1.7 1.6 1.5 1.4 1.3 1.2   R
159.5 155.4 150.8 145.7 140.0 133.7 126.7 118.9  110.1  100.3 89.5 77.3 59.2  Cases 
Severe Pandemic 
Moderate Pandemic 
1.1
52.2 50.9 49.3 47.7 45.8 43.8 41.5 38.9 36.0 32.8 29.3 25.3 19.4 AR, %  6.3
19.3
Figure 1. Baseline inﬂuenza illness attack rates (AR, %) and number of cases (millions) based on the model and a US population of 305.5 million
people for reproductive number (R) values ranging from 1.1 to 2.4.
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(a 6.3%–19.4% illness attack rate) would occur among the
305.5 million people in the United States during a mild
seasonal inﬂuenza outbreak (R ¼ 1.1–1.2) at baseline.
These numbers are consistent with previous estimates. For
example, Molinari et al. (28) estimated that 24.7 million
cases occur annually in a typical inﬂuenza season (an
8.5% illness attack rate based on the 2003 US population).
Under a severe pandemic scenario, if R ¼ 2.4, nearly 160
million cases would be expected in the United States (a
52.2% illness attack rate) based on our model.
The higher the vaccine coverage in children, the greater
the reduction in the overall attack rate, the age-speciﬁc at-
tack rates, and the number of cases for a given value of R,
regardless of whether the vaccine is well matched or poorly
matched to the circulating strain (Tables 2 and 3, Figures 2
and 3). The relation between increasing values of R and the
absolute difference between illness attack rates for a given
level of vaccine coverage compared with baseline is non-
monotonic. The greatest absolute difference in overall at-
tack rates due to vaccination compared with baseline occurs
at low to moderate values of R (R ¼ 1.2–1.5). Within this
Table 2. Homologous Vaccine: Comparison of Numbers of Inﬂuenza Cases (Millions)
a Under 6 Different Vaccination Strategies as the
Reproductive Number (R) Ranges From 1.1 to 2.4
R
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1 2.2 2.3 2.4
Baseline 19.3 59.2 77.3 89.5 100.3 110.1 118.9 126.7 133.7 140.0 145.7 150.8 155.4 159.5
30% vaccine coverage
TIV 1.0 5.4 30.4 59.6 74.1 85.3 95.4 104.4 112.4 119.6 126.1 131.9 137.1 141.8
LAIV 0.8 3.9 23.6 54.4 70.8 82.2 92.2 101.3 109.5 116.7 123.3 129.1 134.4 139.1
Additional cases prevented by LAIV 0.2 1.5 6.8 5.1 3.3 3.1 3.2 3.0 2.9 2.9 2.8 2.9 2.7 2.7
50% vaccine coverage
TIV 0.2 0.6 2.8 17.1 46.8 65.4 77.2 87.3 96.4 104.4 111.7 118.1 123.9 129.1
LAIV 0.2 0.4 1.4 9.3 35.4 58.5 71.7 82.0 91.2 99.4 106.7 113.3 119.2 124.4
Additional cases prevented by LAIV 0.0 0.2 1.3 7.7 11.3 6.9 5.5 5.3 5.2 5.0 5.0 4.8 4.7 4.7
70% vaccine coverage
TIV 0.1 0.2 0.3 1.0 5.3 23.8 52.0 67.2 78.1 87.3 95.6 102.9 109.5 115.2
LAIV 0.1 0.1 0.2 0.5 1.9 11.4 37.7 58.0 70.3 80.0 88.4 95.9 102.6 108.6
Additional cases prevented by LAIV 0.0 0.0 0.1 0.5 3.4 12.4 14.3 9.3 7.8 7.4 7.2 7.0 6.8 6.7
Abbreviations: LAIV, trivalent live, attenuated inﬂuenza vaccine; TIV, trivalent inactivated inﬂuenza vaccine.
a The expected number of cases is based on a US population of 305.5 million.
Table 3. Heterologous Vaccine: Comparison of Numbers of Inﬂuenza Cases (Millions)
a Under 6 Different Vaccination Strategies as the
Reproductive Number (R) Ranges From 1.1 to 2.4
R
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1 2.2 2.3 2.4
Baseline 19.3 59.2 77.3 89.5 100.3 110.1 118.9 126.7 133.7 140.0 145.7 150.8 155.4 159.5
30% vaccine coverage
TIV 2.6 18.8 54.9 74.7 87.1 98.1 107.9 116.6 124.5 131.5 137.8 143.4 148.5 152.9
LAIV 2.0 12.4 45.9 68.6 81.1 92.0 101.7 110.5 118.3 125.3 131.5 137.2 142.1 146.7
Additional cases prevented by LAIV 0.6 6.4 9.1 6.1 6.0 6.1 6.2 6.1 6.2 6.2 6.2 6.2 6.4 6.2
50% vaccine coverage
TIV 0.8 4.1 24.0 59.7 76.6 88.7 99.4 108.9 117.4 125.0 131.8 137.8 143.3 148.2
LAIV 0.5 2.1 12.3 44.9 66.0 78.4 89.1 98.5 107.0 114.6 121.3 127.4 132.8 137.7
Additional cases prevented by LAIV 0.3 2.0 11.7 14.8 10.6 10.3 10.4 10.4 10.4 10.4 10.4 10.4 10.5 10.5
70% vaccine coverage
TIV 0.3 1.0 5.2 27.8 60.6 77.4 89.6 100.1 109.5 117.8 125.1 131.7 137.6 142.9
LAIV 0.2 0.4 1.6 10.8 38.5 61.9 74.7 85.3 94.7 103.0 110.3 117.0 122.9 128.1
Additional cases prevented by LAIV 0.1 0.5 3.6 17.0 22.1 15.5 14.9 14.7 14.8 14.7 14.8 14.8 14.7 14.8
Abbreviations: LAIV, trivalent live, attenuated inﬂuenza vaccine; TIV, trivalent inactivated inﬂuenza vaccine.
a The expected number of cases is based on a US population of 305.5 million.
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lute beneﬁt of vaccination occurs at slightly higher values of
R. If the vaccines are well matched to the circulating in-
ﬂuenza strain, vaccinating 70% of children could prevent
as many as 98.7 million cases during a severe seasonal in-
ﬂuenza outbreak or a moderate pandemic, depending on the
transmission intensity (Table 2; 70% vaccination coverage,
LAIV, R ¼ 1.6). If the vaccines are poorly matched, vac-
cinating 70% of children could prevent as many as 78.7
million cases during a severe seasonal inﬂuenza outbreak,
depending on the transmission intensity (Table 3; 70% vac-
cination coverage, LAIV, R ¼ 1.4).
There is also a nonmonotonic relation between the value
of R and the absolute difference in the reduction in the
number of cases when comparing vaccinating children with
LAIV and with TIV. Again, the greatest difference in the
number of cases prevented when comparing the 2 vaccines
was observed at intermediate values of R for all scenarios.
For example, if the vaccines are poorly matched to the
circulating inﬂuenza strain and vaccine coverage is high
(70%), LAIV could prevent an additional 22.1 million in-
ﬂuenza cases in the population beyond the number of cases
prevented by TIV alone (Table 3; R ¼ 1.5), given the efﬁ-
cacies modeled. In our model, LAIV, compared with TIV,
was assigned higher VESP,V E P, and VEI values based on
our best guesses for these efﬁcacies from previous work (8).
The higher the vaccine efﬁcacies, the greater the numbers of
inﬂuenza cases that can be prevented.
Regardless of transmission intensity, children have higher
attack rates than adults at baseline (Figure 3). Vaccinating
70% of children with a well-matched inﬂuenza vaccine sub-
stantially reduces the attack rates for both children and
adults at low to moderate levels of transmission intensity
(R ¼ 1.1 1.5). The difference between the baseline attack
rates and the age-speciﬁc attack rates at higher levels of
transmission intensity is greater for children than for adults.
Children experience a greater reduction in age-speciﬁc at-
tack rates with the intervention modeled because they ben-
eﬁt from the direct protection of vaccination and the indirect
effects, whereas the reduction in the attack rates for adults
results from only the indirect effects of vaccinating children.
The age-speciﬁc illness attack rates at lower vaccination
coverage levels are qualitatively similar to those at higher
coverage levels, but the rise in the attack rates occurs at
lower values of R for lower vaccination coverage levels
and increases more rapidly (results not shown).
Finally, we observed strong indirect, total, and overall
effects of inﬂuenza vaccination at lower values of R with
high vaccination coverage (Figure 4). The indirect effects in
both adults and children were similar regardless of trans-
mission intensity. The indirect vaccine effects in both
groups declined rapidly after R ¼ 1.2 1.6, depending on
the coverage, indicating that as the level of transmission
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Figure 2. Inﬂuenza illness attack rates, at baseline and after 70% of
children are vaccinated, for a range of values of the reproductive
number (R) for both homologous and heterologous vaccine.
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is homologous.
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Figure 4. Indirect, overall, and total vaccine effects (VE) for adults
and children when 70% of children are vaccinated with live, attenu-
ated vaccine for a range of values of the reproductive number (R)
when the vaccine is homologous.
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directly. At values of R   2.0, the intensity of transmission
effectively overwhelms the ability of the vaccine to protect
indirectly, given the greater level of exposure to infection.
The value of R at which the indirect effects began to decline
depends on the vaccination coverage. With lower vaccina-
tion coverage in children, the decline in indirect vaccine
effects occurs at lower values of R. This shift in the decline
of the indirect effects in adults is illustrated for all 3 levels of
vaccine coverage when both LAIV and TIV are well
matched to the circulating inﬂuenza strain (Figure 5). The
indirect effects of TIV were slightly lower than the VEIndirect
observed for LAIV regardless of transmission intensity, but
the shape of the trends was qualitatively similar.
The total effect of vaccination in children remained rela-
tively high regardless of the severity of the outbreak or the
coverage level when the vaccines were well matched to
the inﬂuenza strain. Both the VEOverall in children and the
VEOverall in the entire population decreased as R increased,
with the initial decline occurring at lower levels of trans-
mission intensity for lower levels of vaccination coverage.
The overall and total effects were higher than the indirect
effects because they account for the direct effect of the
vaccine in the vaccinated children in the population as well
as the indirect effects of the vaccination intervention.
When thevaccines were poorly matched to the circulating
inﬂuenza strains, the same qualitative trends were observed.
However, the decline in indirect, total, and overall vaccine
effects occurred at lower levels of transmission intensity and
decreased more rapidly compared with the well-matched
scenario (results not shown).
DISCUSSION
The results of our stochastic simulation model demon-
strate that vaccinating children against inﬂuenza can sub-
stantially reduce inﬂuenza illness in the overall population
given a wide range of scenarios. In a mild inﬂuenza season
(R ¼ 1.1), approximately 19 million cases of inﬂuenza in
the United States could be prevented if 70% of children were
vaccinated. The greatest reduction in the number of cases
compared with baseline was achieved with 70% vaccination
coverage in children when the vaccine is homologous and
transmission intensity is intermediate (R ¼ 1.6). In this in-
stance, approximately 98.7 million cases in the United States
could be prevented. Even at low levels of vaccination, our
model predicts that millions of cases of inﬂuenza can be
prevented by targeted vaccination of children.
Vaccinating children against inﬂuenza produces both di-
rect beneﬁts in the children vaccinated and indirect beneﬁts
in the rest of the population. The indirect effects for both
children and adults were high at low to intermediate values
of R, indicating that inﬂuenza vaccination can provide sub-
stantial herd immunity when transmission intensity is low to
intermediate. As transmission intensity increases, the indi-
rect effects of vaccinating children decline rapidly, even at
high vaccination coverage levels.
The beneﬁt of vaccination depends upon the components
of vaccine efﬁcacy for a given vaccine. In our model, LAIV
and TIV were assigned the same VES and relatively similar
VESP and VEI. However, for LAIV, the VEP assigned in
both homologous and heterologous seasons was higher.
The higher VEP reduces inﬂuenza illnesses directly, by pre-
venting illness, and indirectly, because asymptomatic indi-
viduals are less infectious. Thevaccine efﬁcacies used in the
model were assigned based on the best available data. How-
ever, there is a need for well-designed epidemiologic ﬁeld
studies in which the components of vaccine efﬁcacy can be
estimated for both vaccines directly. Belshe et al. (29) re-
ported that LAIV was 50% more efﬁcacious than TIV
against clinical infection in young children. There is some
evidence that, compared with the inactivated vaccine, LAIV
is easier to administer, is more acceptable to children, and
induces broader cross-protective immunity (30–33).
Children experience high seasonal inﬂuenza attack rates
and bear a large burden of disease (1, 2, 28). Evidence
indicates that targeted vaccination of children has the beneﬁt
of reducing the burden of disease in this age group and the
added public health advantage of reducing morbidity and
mortality in the entire population (4, 22, 34). Strategies for
vaccinating populations and allocating vaccines to reduce
inﬂuenza morbidity and mortality have been modeled pre-
viously (35–40). Despite various modeling approaches and
assumptions, several studies have found that vaccinating
schoolchildren could reduce the overall incidence of inﬂu-
enza illness in the population and the overall number of
deaths expected (35, 37, 38, 40). The economic beneﬁts of
vaccination strategies that target children for inﬂuenza vac-
cination have also been demonstrated (34, 41–43). Prospec-
tively designed ﬁeld studies that evaluate strategies for
vaccinating children are needed to test these modeling re-
sults in the community, as has been noted (44).
In response to the outbreak of novel inﬂuenza A (H1N1)
in the spring of 2009, health ofﬁcials have called for the
production of a new inﬂuenza vaccine to mitigate spread
of this strain. Yet, plans for the use of such a vaccine have
not been determined. Early reports indicate that the attack
rate pattern for the novel inﬂuenza A (H1N1) strain is sim-
ilar to spread of the Asian pandemic inﬂuenza A (H2N2) in
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Figure 5. Indirect vaccine effects (VE) for adults after vaccinating
children with inﬂuenza vaccine for a range of values of the reproduc-
tive number (R) when the vaccine is homologous.
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with high spread among children (45). Therefore, the results
of our modeling study can be used to address this situation.
Indeed, our results indicate that the greatest beneﬁt of vac-
cinating children is achieved at intermediate values of R,
and that the beneﬁt is maximized when vaccination cover-
age is high and the vaccine is well matched. With a high
vaccination rate (70%) and awell-matched vaccine, as many
as 95–98.7 million additional cases could be prevented by
vaccinating children. Vaccinating just 30% of children with
an inﬂuenza vaccine, even if poorly matched, could prevent
an additional 12–20.9 million cases in the United States if R
ranged from 1.4 to 1.6. The typical inﬂuenza season in the
Northern Hemisphere is just months away, and health ofﬁ-
cials will soon need to decide how to best allocate a newly
developed vaccine to mitigate the impending threat of novel
inﬂuenza A (H1N1). Our results build upon an increasing
body of research and provide strong evidence that vaccinat-
ing children against inﬂuenza can substantially reduce
population-level attack rates given a wide range of scenarios.
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